Comparative Pharmacology
Head-to-head clinical analysis: CYANOKIT versus VORAXAZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYANOKIT versus VORAXAZE.
CYANOKIT vs VORAXAZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxocobalamin, a form of vitamin B12, acts as a scavenger of cyanide ions by binding with them to form cyanocobalamin, which is then excreted in urine. It has a higher affinity for cyanide than cytochrome c oxidase, thereby restoring mitochondrial function.
Glucarpidase is a recombinant bacterial enzyme that hydrolyzes the glutamate residue from methotrexate and its metabolites, converting them to nontoxic metabolites.
5 g intravenous infusion over 15 minutes for adults and pediatric patients weighing >=40 kg. A second dose of 5 g may be administered if needed based on clinical response.
2000 units intravenously over 5 minutes as a single dose.
None Documented
None Documented
The terminal elimination half-life of hydroxocobalamin is approximately 24-28 hours in healthy adults; in cyanide poisoning, the half-life may be prolonged due to reversible binding to cyanide.
Terminal elimination half-life is approximately 10 hours (range 6-16 hours) in patients with normal renal function. In patients with methotrexate-induced renal impairment, half-life may be prolonged up to 20-30 hours. Clinical context: the half-life determines the timing of repeat dosing or monitoring; a single dose typically reduces methotrexate levels by >97% within 15 minutes.
Primarily renal elimination as hydroxocobalamin and cyanocobalamin; >90% of an intravenous dose is excreted in urine within 72 hours, with the remainder eliminated in feces via biliary excretion.
Voraxaze (glucarpidase) is a recombinant enzyme that rapidly cleaves circulating methotrexate into inactive metabolites (DAMPA and glutamate). It is not significantly renally or hepatically excreted; rather, it is a high-molecular-weight protein that is catabolized via proteolysis. The majority of the administered dose is metabolized and eliminated as smaller peptides and amino acids. Less than 1% is excreted unchanged in urine.
Category C
Category C
Antidote
Antidote